Biotia is a health-tech company based in New York, NY, that develops genomics-based diagnostics and AI-powered software to identify microorganisms, antimicrobial resistance, and infectious diseases rapidly and accurately[1][2][3][4]. It builds products like GeoSeeq for researchers, which detects and predicts outbreaks by integrating sequencing data with AI to create global health maps and support local labs in underserved areas, and BIOTIA-ID (including a urine assay) for clinicians, offering validated tests for immunocompromised patients and complicated infections with high sensitivity and specificity[4]. Biotia serves clinicians, researchers, hospitals, and global health initiatives, solving problems like slow legacy diagnostics, high failure rates in pathogen detection, and the need for portable tools in remote or extreme environments such as space[1][3][4]. As a 2016 Cornell Tech spinout at Series A stage with 11-50 employees, it operates a NYS CLIA-certified lab (accredited in 2020) affiliated with SUNY Downstate, enabling trusted clinical testing across most US states and showing growth through partnerships like its collaboration with Korean firm Boryung for space and remote diagnostics[1][2][3].
Biotia emerged as a spinout from the Jacobs Technion-Cornell Institute at Cornell Tech in 2016, founded by Dr. Niamh O'Hara (Co-Founder & CEO, Runway Startup Postdoc 2015) and Dr. Christopher Mason (Co-Founder & Global Director, Weill Cornell Medicine)[1][2]. O'Hara and Mason, leveraging expertise in sequencing and AI from Cornell's innovative ecosystem, addressed gaps in infectious disease detection by combining next-generation sequencing with proprietary software for precision diagnostics[1][2][3]. Early traction included achieving full CLEP and high-complexity CLIA certification from the NY State Department of Health in 2020—the strictest in the US—enabling clinical sample processing and building trust in their reference library of microbes[1]. Pivotal moments feature the launch of the GeoSeeq Watchtower Program with 12 global sites for early pathogen detection and presenting a pandemic early warning vision at the UN General Assembly alongside WHO and others[4].
Biotia rides the genomics-AI convergence trend in health-tech, accelerating precision medicine amid rising antimicrobial resistance, climate-driven outbreaks, and post-pandemic surveillance needs[1][3][4]. Timing is ideal as global travel, land-use changes, and program dismantlings heighten threats, while portable sequencing enables "leapfrogging" in underserved areas—e.g., its Watchtowers connect diagnostic deserts to global insights[4]. Market forces like space health innovation (Moon/Mars missions) and regulatory approvals favor its clinically validated platform, positioning it to influence ecosystems by providing the world's leading microbe library, early warning systems, and tools for vaccines/therapeutics[1][3][4]. As a Cornell spinout, it exemplifies academic-tech translation, enhancing startup momentum in biotech via partnerships and UN/WHO visibility[1][4].
Biotia is poised to scale its Watchtower network and space-adapted diagnostics, potentially dominating portable infectious disease monitoring as climate threats intensify[3][4]. Trends like AI-driven outbreak prediction, metagenomic portability, and global health equity will propel growth, with Series A funding enabling expansion beyond Earth[2]. Its influence may evolve from niche diagnostics to a core pandemic shield, integrating more real-time data for proactive interventions—reinforcing its founding mission to fight infections anywhere, anytime[1][3]. This positions Biotia as a resilient player in an era demanding rapid, borderless health defense.
Biotia has raised $8.0M in total across 1 funding round.
Biotia's investors include Jenny Fielding, Scott Hartley, OCA Ventures.
Biotia has raised $8.0M across 1 funding round. Most recently, it raised $8.0M Series A in August 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2022 | $8.0M Series A | Jenny Fielding, Scott Hartley, OCA Ventures |
